Long term magnesium supplementation influences favourably the natural evolution of neuropathy in Mg-depleted type 1 diabetic patients (T1dm)

Magnesium Research

Volumn 17, Issue 2, 2004, Pages 109-114

  De Leeuw, Ivo ^a,b   Engelen, Wendy ^a   De Block, Christophe ^a   Van Gaal, Luc ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Magnesium depletion; Magnesium supplementation; Neuropathy; Type 1 diabetes

Indexed keywords

MAGNESIUM;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE SEVERITY; ELECTROMYOGRAM; ERYTHROCYTE; FEMALE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; STATISTICAL SIGNIFICANCE; VITAMIN SUPPLEMENTATION;

ADULT; DIABETES MELLITUS, TYPE 1; DIABETIC NEUROPATHIES; DIETARY SUPPLEMENTS; FEMALE; HUMANS; MAGNESIUM; MALE;

MARTES PENNANTI;

EID: 4243187066     PISSN: 09531424     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Mather HM, Nisbet JA, Burton GH, Poston GJ, Bland JM, Pilkington TRE. Hypomagnesemia in diabetes. Clin Chim Acta 1979; 95: 235-42.
2. Garland HO. New experimental data on the relationship between diabetes mellitus and magnesium. Magnes Res 1992; 5: 193-202.
3. Tosiello L. Hypomagnesemia and diabetes mellitus, a review of clinical implications. Arch Intern Med 1996; 156: 1143-8.
4. McNair P, Christensen MS, Christiansen C, Madsbad S, Transbøl IB. Renal hypomagnesaemia in human diabetes mellitus. Eur J Clin Invest 1982; 12: 81-5.
5. Sjögren A, Floren CH, Nilsson A. Magnesium deficiency in IDDM is related to the level of glycosylated hemoglobin. Diabetes 1986; 35: 459-63.
6. Ponder SW, Brouhard BH, Travis LB. Hyperphosphaturia and hypermagnesuria in children with IDDM. Diab Care 1990; 13: 437-41.
7. Djurhuus MS, Skøtt P, Vaag A, Hother-Nielsen O, Andersen P, Parving HH, Klitgaard NAH. Hyperglycemia enhances renal magnesium excretion in type 1 diabetic patients. Scand J Clin Lab Invest 2000; 60: 403-10.
8. Djurhuus MS, Skøtt P, Hother-Nielsen O, Klitgaard NAH, Beck-Nielsen H. Insulin increases renal magnesium excretion. Diabet Med 1995; 12: 664-9.
9. De Block C, De Leeuw I. Associated thyrogastric autoimmunity increases the prevalence of low erythrocyte magnesium in type 1 diabetes. Magnes Res 1999; 12: 279-85.
10. De Leeuw I, Vertommen J, Abs R. The Mg content of the trabecular bone in diabetic subjects. Biomedicine 1978; 29: 16-7.
11. Durlach J. Magnesium in clinical practice. London: John Libbey, Company Ltd 1988, pp 1-360.
12. Lima MdL, Cruz T, Pousada JC, Rodrigues LE, Barbosa K, Canguçu V. The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. Diab Care 1998; 21: 682-6.
13. Engelen W, Bouten A, De Leeuw I, De Block C. Are low magnesium levels in type 1A diabetes associated with EMG signs of polyneuropathy? Magnes Res 2000; 13: 197-203.
14. Millart H, Durlach V, Durlach J. Red blood cell magnesium concentrations: analytical problems and significance. Magnes Res 1995; 8: 65-76.
15. Ward JD, Tesfaye S. Pathogenesis of diabetic neuropathy. In: Textbook of diabetes eds J Pickup, G Williams G. Oxford UK: Blackwell Science Ltd 1997, pp 49.1-49.19.
16. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4000 patients observed. Diab Care 1978; 1: 168-88, 252-63.
17. DCCT research Group. Factors in the development of diabetic neuropathy. Diabetologia 1988; 37: 476-83.
18. Liveson JA, Dang MA. Laboratory reference for Clinical neurophysiology, Philadelphia: FA Davis Company 1992.
19. Van Roelen W, Van Gaal L, Van Rooy P, De Leeuw I. Serum and erythrocyte magnesium levels in type 1 and type 2 diabetics. Acta Diabetol Lat 1985; 22: 185-90.
20. Soroku Y. Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes Metab Rev 1995; 11: 193-225.
21. Paolisso G, Tirelli A, Coppola L, Verrazzo G, Pizza G, Sgambato S, D'Onofrio F. Magnesium administration reduces platelet hyperaggregability in NIDDM. Diab Care 1989; 12: 167-8.
22. + ATPase regulation involved in the pathogenesis of diabetic neuropathy? Diabetes 1988; 37: 688-93.
23. 2+ in the etiology of diabetic complications. Diabetes 1992; 41: 35-39.
24. Van Dam PS, Van Asbeck BS, Erkelens DW, Marx JJM, Gispen WH, Bravenboer B. The role of oxidative stress in neuropathy and other diabetic complications. Diabetes Metab Rev 1995; 11: 181-92.
25. Cameron NE, Cotter MA, Archibald V, Dines KC, Maxfield EK. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and STZ-induced diabetic rats. Diabetologia 1994; 37: 449-59.
26. Freedman AM, Mak IT, Stafford RE, Dickens BF, Cassidy MM, Muesing RA, Weglicki WB. Erythrocytes from magnesium-deficient hamsters display an enhanced susceptibility to oxidative stress. Am J Physiol 1992; 262: C1371-5.
27. Rayssiguier Y, Gueux E, Bussière L, Durlach J, Mazur A. Dietary magnesium affects susceptibility of lipoproteins and tissues to peroxidation in rats. J Am Coll Nutr 1993; 12: 133-7.
28. De Leeuw I, Engelen W, Aerts P, Schrans S. Effect of intensive magnesium supplementation on the in vitro oxidizability of LDL and VLDL in Mg-depleted type 1 diabetic patients. Magnes Res 1997; 10: 135-41.
29. Mac Cann VJ, Davis RE. Serum pyridoxal concentrations in patients with diabetic neuropathy. Aust NZ J Med 1978; 8: 259-61.
30. Planells E, Serma A, Sanchez-Morito N, Aranda P, Slopis J. Effect of Mg deficiency on vitamin B12 and B6 status in the rat. J Am Coll Nutr 1997; 16: 352-6.